HeraMED completes $1.98 million placement

• Firm commitments of $1.98 million (before costs) in a single tranche placement
• $1.98 million placement at 1.2 cents per share, a ~4.8% discount to the 15-day VWAP
• Proceeds to support execution of near-term commercial opportunities in the U.S., Australia, and Europe

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, has received firm commitments to raise $1.98 million (before costs) through a private placement of 165 million fully paid ordinary shares at an issue price of $0.012 per share. The placement attracted strong support from both new and existing institutional and sophisticated investors, underlining continued confidence in the Company's strategic direction and commercialisation progress. The proceeds of the Placement will fund working capital to support commercial deployments, pilots and integration of HeraCARE into large health systems, private clinics and a number of platforms in the U.S. as well as Australia and Europe. Westar Capital Limited was engaged as Lead Manager to the Placement and receives a 6% capital raising fee and will also receive 20 million options using the Company's capacity under ASX Listing Rule 7.1 on the following terms: with an exercise price of 2 cents, an expiry date of 24 December 2028, transferable and exercisable upon issue, unlisted, and ranked equally to other options of the company.

The placement provides critical working capital and extends HeraMED's cash runway as the company focuses on unlocking high-impact opportunities, building scale, and delivering value to mothers, clinicians, and shareholders alike.